HomeQuestion

How would you manage grade 3 treatment-emergent diabetes mellitus (HbA1c of 11.1, anti-GAD65) in a patient with ES-SCLC on atezolizumab maintenance?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

How does neoadjuvant chemo-immunotherapy impact your decision on hypofractionation/dose fractionation for locally advanced NSCLC, now getting RT alone?

How do you approach treatment selection for patients with non-small cell lung cancer who have uncommon EGFR mutations compared to those with common mutations?

How do you approach treatment selection among novel bispecific antibodies and ADCs for patients with EGFR+ NSCLC previously treated with 3rd generation EGFR inhibitors?

When will you select Dato-DXd for patients with EGFR-mutated non-small cell lung cancer?

Would you use consolidation immunotherapy after chemoradiation for patients with stage III NSCLC and EGFR amplification?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.